Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center. It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer.
Proton therapy targets cancer cells more precisely than traditional x-ray photon therapy, and results in less damage to surrounding healthy tissue and sensitive organs such as the brain, heart, spine, and lungs. This provides a significant reduction in acute adverse events and hospitalization along with a decreased risk of secondary malignancies when compared to traditional x-ray photon therapy. It is the preferred modality for treating pediatric patients, who are particularly susceptible to the potential side effects of radiation therapy.
“Bringing the most advanced technology to serve our patients with the highest quality care is essential,” said Mark Bonnen, MD, chief medical officer of the Mays Cancer Center. The MEVION S250i with HYPERSCAN has advanced the benefits of proton therapy by enabling faster and sharper delivery of therapeutic radiation. The system’s leading-edge clinical capabilities, combined with its compact, affordable design, industry-leading ramp-up time, and environmentally friendly energy use have helped expand access to proton therapy to patients worldwide. The new proton center will be built adjacent to The University of Texas Health Science Center’s Greehey Children’s Cancer Research Institute and the world renowned, NCI-designated, Mays Cancer Center that will provide clinical and research expertise in the new center and oversee all research and academic training.
“Mevion is honored to partner with UT Health San Antonio and Proton International to bring our life-saving technology close to home for patients in South Texas,” said Tina Yu, Ph.D., chief executive officer and president of Mevion. “In the past 5 years, proton therapy has moved away from large multi-room centers to single-room systems and with this system, our seventh NCI-designated center partnership, it solidifies our 62% market leadership in the U.S. compact proton therapy market.”
“The Proton International team is pleased to be working with our partners to bring this important technology to the citizens of San Antonio and the surrounding region. Our collective vision is to assure this technology will be available in the fight against cancer and will make a real difference in patients’ lives” said Chris Chandler, CEO of Proton International.
Source: Mevion Medical Systems.